A Multicenter, Randomized, Double-blind, Parallel ControlledSingle-dose Phase I Study Comparing the Pharmacokinetic and Safety Similarities of Recombinant Anti IgE Humanized Monoclonal Antibody (HS632) With Omalizumab a in Healthy Subjects
Latest Information Update: 25 Sep 2023
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors Hisun BioRay
Most Recent Events
- 20 Aug 2020 Planned initiation date changed from 8 Oct 2020 to 15 Oct 2020.
- 29 Jul 2020 Planned initiation date changed from 8 Jun 2020 to 8 Oct 2020.
- 30 Apr 2020 New trial record